Press release
Updated Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO 2017
- Phase I/II trial shows significant responses of HPV16-positive patients with late-stage cervical cancerLeiden, The Netherlands, May 23, 2017 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that an update of the results of a company-sponsored clinical Phase I/II trial in late-stage cervical cancer patients (ISA101-CervISA) will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017, Chicago, IL, USA).
A poster presentation will be held by Winald Gerritsen MD, PhD., one of the Principle Investigators of the CervISA study, on Thursday, June 3, 2017:
“Poster Session Gynecologic Cancer”: 1:15PM – 4:45PM
The data will be based on the abstract titled "Association of T cell responses after vaccination with HPV16 long peptides for late stage cervical cancer with prolonged survival" (abstract no. 5525). The Company intends to publish the data in a peer-reviewed journal later this year.
###
About ISA Pharmaceuticals
ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT® technology, which have the potential to generate safe and effective immunologic responses with a known mechanism of action. Synthetic long peptides are broadly applicable to multiple targets and ideally suited for monotherapy, as essential components in combination with conventional cancer treatments, and with novel immunomodulators such as Nivolumab. SLP® immunotherapies are designed to fully harness and direct the body's own defenses towards fighting the disease. In addition, ISA has begun to develop MyISA®, a personalized SLP® immunotherapy, targeting tumor-specific, mutation-derived neo-antigens. These SLP®s are based on the analysis of immunogenic DNA mutations in a tumor sample, and designed and synthesized for each individual patient.
ISA´s most advanced clinical-stage immunotherapeutic is ISA101, an SLP® immunotherapy targeting human papillomavirus (HPV)-induced diseases. It is currently in clinical development in advanced and recurrent cervical cancer, incurable HPV16-positive solid tumors (such as small cell carcinoma of head and neck SCCHN) and anal intraepithelial neoplasia (AIN). A clinical Phase II combination trial with ISA101 and Nivolumab is completed and will soon be reported by the MD Anderson Cancer Center in the US. Clinical proof-of-concept has been established in vulvar intraepithelial neoplasia (VIN), a pre-cancerous disease caused by HPV.
The company was founded in 2004 by Aglaia Oncology Fund and is based in Leiden, The Netherlands. For more information, please visit www.isa-pharma.com
SLP®, AMPLIVANT® and MyISA® are registered trademarks in Europe.
ISA Pharmaceuticals
Miranda Molenaar
J.H. Oortweg 19
NL-2333 CH Leiden
The Netherlands
T: +31 71 33 22 310
F: +31 71 33 22 311
E: info@isa-pharma.com
Contact & Media Inquiries:
akampion
Dr. Ludger Wess, Ines-Regina Buth
Managing Partners
Tel. +49 40 88 16 59 64, Tel. +49 30 23 63 27 68
info(at)akampion.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Updated Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO 2017 here
News-ID: 547296 • Views: …
More Releases from ISA Pharmaceuticals
ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeti …
- Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentation
Leiden, The Netherlands, March 28, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will give an oral presentation at the upcoming AACR Annual Meeting 2019 in Atlanta, GA, USA, on March 31, 2019.
The presentation titled "A strong HPV-specific T-cell response after chemo-immunotherapy for advanced…
ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Cornelis Melief Receiv …
- Recognition for outstanding and innovative cancer research
Leiden, The Netherlands, March 19, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019 from the American Association of Cancer Research (AACR) and the Cancer Research Institute.
The AACR-CRI Lloyd J. Old Award in Cancer Immunology recognizes an active…
ISA Pharmaceuticals Announces Start of Phase 2 Combination Trial of ISA101b and …
- ISA101b and Cemiplimab studied in patients with platinum refractory HPV16-positive oropharyngeal cancer (OPC)
Leiden, The Netherlands, January 21, 2019 – ISA Pharmaceuticals B.V., a clinical-stage company dedicated to the development of rationally designed immunotherapeutics, today announced randomization of the first patient in a Phase 2 combination trial of its lead compound ISA101b and Regeneron´s (NASDAQ: REGN) anti-PD-1 antibody cemiplimab (REGN2810).
This double blind, placebo-controlled, randomized, phase 2 study (NCT03669718)…
ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief to Present …
Leiden, The Netherlands, January 16, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Cornelis Melief will give a talk at the upcoming Keystone Cancer Vaccines Conference in Vancouver, BC, Canada, January 20-24, 2019.
The talk titled "Therapeutic HPV16 Vaccination Is Effective as Monotherapy in Pre-Malignant Disease, but Requires Combination Treatment in HPV16-Induced Cancers" is scheduled for Thursday, January 24, 2019, at 17:00…
More Releases for SLP®
Cleveland State University's Online Master's in CSD Prepares Students for Multi- …
Image: https://www.globalnewslines.com/uploads/2025/04/1745391100.jpg
With the upcoming implementation of the Audiology & Speech-Language Pathology Interstate Compact (ASLP-IC), many speech-language pathologists (SLPs) may expand their practice across participating states. Cleveland State University's (CSU) online Master's in Communication and Speech Disorders [https://onlinelearning.csuohio.edu/programs/online-masters-communication-sciences-disorders] (CSD) program prepares graduates for rewarding careers, while supporting them in navigating evolving SLP opportunities.
The ASLP-IC allows eligible SLPs who hold an active speech-language pathology license in their home state - and meet…
Psicologos SLP: Pioneering Cognitive-Behavioral Therapy for Effective Mental Hea …
Image: https://www.getnews.info/wp-content/uploads/2024/08/1724123163.png
Experts at Psychologists SLP help clients manage themselves in a healthy way, providing the tools and techniques necessary to manage stress and daily worries.
Renowned for its expert application of cognitive-behavioral therapy (CBT), Psicologos SLP [https://psicologosslp.com/] has garnered a reputation for delivering tangible results in the field of psychology, helping to guide patients for over 15 years toward mental health and well-being with its expertise and comprehensive care.
At the…
Slp Pcb Market Expansion at 5.29% CAGR by 2032
SLP PCB Market Overview
The SLP (Substrate-Like PCB) Market is an evolving segment within the broader printed circuit board (PCB) industry, driven by the increasing demand for miniaturized and high-performance electronic devices. As of 2023, the SLP PCB market was valued at approximately USD 1.92 billion. The market is expected to grow steadily, reaching USD 2.02 billion in 2024 and further expanding to USD 3.05 billion by 2032. This growth represents…
Psicologos SLP Cognitive-Behavioral Therapy Clinic Leads the Way in Mental Well- …
Image: https://www.getnews.info/wp-content/uploads/2024/05/1715731549.png
Psicologos SLP is a leading mental health clinic helping people manage their daily stresses to function effectively and lead productive and fulfilling lives.
Committed to enhancing mental well-being through advanced therapeutic practices, Psicologos SLP [http://psicologosslp.com/] has earned a stellar reputation in the field of cognitive-behavioral therapy (CBT), combining evidence-based treatment and an unwavering commitment to clinical excellence to deliver unparalleled psychological services, helping each individual achieve a full and…
Asia Pacific Substrate-Like PCB (SLP) Market Size, cap of $ 25,000.1 million ove …
Asia Pacific substrate-like PCB (SLP) market will grow by 15.6% annually with a total addressable market cap of $ 25,000.1 million over 2022-2031, driven by SLPs ability to enable faster transmission while simultaneously giving the manufacturers more freedom to design their product, increasing R&D activities for technological advancements, the rising prevalence of smart consumer electronics such as smartphones and wearable devices, and the growing demand for effective connectivity solutions and…
Europe Substrate-Like PCB (SLP) Market Size Boosting The Growth Worldwide
Europe substrate-like PCB (SLP) market was valued at $ 94.5 million in 2021 and will grow by 11.4% annually over 2021-2031, driven by SLPs ability to enable faster transmission while simultaneously giving the manufacturers more freedom to design their product, increasing R&D activities for technological advancements, the rising prevalence of smart consumer electronics such as smartphones and wearable devices, and the growing demand for effective connectivity solutions and the growing…
